AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30836637 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in liver fat after 12 weeks (NAFLD: 32.9 ± 9.5%, No NAFLD: 6.3 ± 4.0%)
Number of subjects: 143
Study 30836637 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in liver fat after 50 weeks (NAFLD: 23.3 ± 4.4%, No NAFLD: 5.0 ± 4.2%)
Number of subjects: 143
Study 30836637 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in biomarkers of liver dysfunction (GGT, ALT, AST)
Number of subjects: 143
Study 30836637 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA IR
Number of subjects: 143
Study 30836637 — intervention group
Group type: EXPERIMENTAL
Intervention: Other metabolic parameters
Number of subjects: 143
Study 28654628 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 0
Study 28654628 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 0
Study 28654628 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 26511146 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 7063
Study 26511146 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 7063
Study 24025377 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S
Number of subjects: 78
Study 24025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement at 72 h
Number of subjects: 78
Study 24025377 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S with ballpoint pen-ruler
Number of subjects: 78
Study 24025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation+ruler at 72 h
Number of subjects: 78
Study 21832297 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling (increased by 10 km/week)
Number of subjects: 98
Study 21832297 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 98
Study 21832297 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling
Number of subjects: 98
Study 19232615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (n=121)
Number of subjects: 240
Study 17082957 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 20
Study 17082957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15239792 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/day molecular iodine for 6 months
Number of subjects: 111
Study 15239792 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/day molecular iodine for 6 months
Number of subjects: 111
Study 15239792 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mg/day molecular iodine for 6 months
Number of subjects: 111
Study 15239792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 11699043 — intervention group
Group type: EXPERIMENTAL
Intervention: Offsprings of NIDDM parents
Number of subjects: 40
Study 11699043 — intervention group
Group type: EXPERIMENTAL
Intervention: Offsprings of NIDDM parents during bed rest
Number of subjects: 40
Study 11699043 — intervention group
Group type: EXPERIMENTAL
Intervention: Offsprings of NIDDM parents in head-up position
Number of subjects: 40
Study 9042633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bed covering system
Number of subjects: 31
Study 9042633 — intervention group
Group type: COMPARATOR
Intervention: Placebo bed covering system
Number of subjects: 31
Study 8192112 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol mouthwashes
Number of subjects: 44
Study 8192112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3285838 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (2.5-30 mg/d)
Number of subjects: 16
Study 3285838 — intervention group
Group type: EXPERIMENTAL
Intervention: pergolide (50-500 micrograms/d)
Number of subjects: 16
Study 30771492 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive FSWs
Number of subjects: 436
Study 30771492 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive FSWs
Number of subjects: 436
Study 30100127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 79
Study 30100127 — intervention group
Group type: COMPARATOR
Intervention: Usual care and workshop on healthy lifestyle
Number of subjects: 79
Study 26898135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Combined Intra‐Renal Surgery (ECIRS)
Number of subjects: 67
Study 26898135 — intervention group
Group type: COMPARATOR
Intervention: Minimally Percutaneous Nephrolithotomy (MPCNL)
Number of subjects: 67
Study 24768981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol, 400 μg, with 100 mL of 5% intravenous glucose (misoprostol arm)
Number of subjects: 150
Study 24768981 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketoprofen, 50 mg/mL, in 100 mL 5% glucose with intravaginal placebo (ketoprofen arm)
Number of subjects: 150
Study 24768981 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo tablets, 100 mL 5% intravenous glucose (placebo arm)
Number of subjects: 150
Study 24768981 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 23140480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (up to 12 group sessions over six weeks)
Number of subjects: 75
Study 23140480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 23140480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sessions attended
Number of subjects: 75
Study 23140480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 75
Study 21073062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2PE preserved hepatitis B vaccine kept on the shelf <12 months (2PE New group)
Number of subjects: 420
Study 21073062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2PE preserved hepatitis B vaccine kept on the shelf >18 months (2PE Old group)
Number of subjects: 420
Study 21073062 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiomersal preserved hepatitis B vaccine [HBV(Thio) group]
Number of subjects: 420
Study 21073062 — intervention group
Group type: COMPARATOR
Intervention: 2PE New and 2PE Old groups
Number of subjects: 420
Study 21073062 — intervention group
Group type: COMPARATOR
Intervention: 2PE groups
Number of subjects: 420
Study 21073062 — intervention group
Group type: COMPARATOR
Intervention: 2PE New and Old groups
Number of subjects: 420
Study 21073062 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 420
Study 21073062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2PE preserved hepatitis B vaccine
Number of subjects: 420
Study 17975184 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication behaviors (including probing, open-ended opportunities to talk, and responsiveness to patient clues) during screening for domestic violence
Number of subjects: 1281
Study 17975184 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider screening for domestic violence
Number of subjects: 1281
Study 17975184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart documentation of domestic violence
Number of subjects: 1281
Study 17166386 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection Yiyoutasai (75 mg/m², every 3 weeks)
Number of subjects: 67
Study 17166386 — intervention group
Group type: COMPARATOR
Intervention: Injection Aisu (75 mg/m², every 3 weeks)
Number of subjects: 67
Study 12003456 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 96
Study 12003456 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 96
Study 12003456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9465815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction (n = 57)
Number of subjects: 120
Study 9465815 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 63)
Number of subjects: 120
Study 8552852 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day seminar on screening for breast cancer and cervical cancer
Number of subjects: 278
Study 8552852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 278
Study 2203467 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic plus steroid
Number of subjects: 40
Study 2203467 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 40
Study 870388 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions of dextran
Number of subjects: 8
Study 870388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 8
Study 870388 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral anticoagulation with cumarins
Number of subjects: 8
Study 870388 — intervention group
Group type: EXPERIMENTAL
Intervention: Aescin
Number of subjects: 8
Study 870388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug prophylaxis)
Number of subjects: 8
Study 31162492 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbinoplasty during septo- or septorhinoplasty
Number of subjects: 73
Study 31162492 — intervention group
Group type: COMPARATOR
Intervention: No turbinoplasty during septo- or septorhinoplasty
Number of subjects: 73
Study 28753102 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt with Bifidobacterium animalis subsp. lactis DN‐173010
Number of subjects: 51
Study 28753102 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 51
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice a day)
Number of subjects: 8144
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg twice a day)
Number of subjects: 8144
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg per day with taper)
Number of subjects: 8144
Study 27116918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8144
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 8144
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 8144
Study 27116918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 8144
Study 24725169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin (two tablets of 0.2 mg once daily)
Number of subjects: 220
Study 24725169 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin (one tablet of 0.2 mg and one tablet of placebo once daily)
Number of subjects: 220
Study 24725169 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin
Number of subjects: 220
Study 24725169 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin
Number of subjects: 220
Study 22858560 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised sensitivity elimination dose
Number of subjects: 96
Study 22858560 — intervention group
Group type: COMPARATOR
Intervention: Standardised 15 min dose
Number of subjects: 96
Study 19328636 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg St John's wort (SJW) active
Number of subjects: 143
Study 19328636 — intervention group
Group type: COMPARATOR
Intervention: Placebo for St John's wort
Number of subjects: 143
Study 19328636 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microm chromium active
Number of subjects: 143
Study 19328636 — intervention group
Group type: COMPARATOR
Intervention: Placebo for chromium
Number of subjects: 143
Study 17127698 — intervention group
Group type: EXPERIMENTAL
Intervention: Short induction therapy with anti-thymoglobulin (ATG) and steroids for 4 days, followed by CellCept and tacrolimus
Number of subjects: 24
Study 15894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg for 4 weeks followed by 10 mg for 4 weeks, n = 22)
Number of subjects: 57
Study 15894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg for 8 weeks, n = 18)
Number of subjects: 57
Study 15894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg for 1 week, 5.0 mg for 3 weeks and 10 mg for 4 weeks, n = 17)
Number of subjects: 57
Study 16531889 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (45 min, 5 days/week)
Number of subjects: 173
Study 16531889 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study 10538640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program with personal invitations, letters, and telephone reminders from peer educators encouraging attendance at three bimonthly nutrition sessions.
Number of subjects: 1528
Study 10538640 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age, breast-feeding, and knowledge of the recommendation to eat five or more servings of fruits and vegetables daily.
Number of subjects: 1528
Study 10538640 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women who already had children.
Number of subjects: 1528
Study 10538640 — intervention group
Group type: COMPARATOR
Intervention: Unmarried women compared with married women and blacks compared with nonblacks.
Number of subjects: 1528
Study 10538640 — intervention group
Group type: COMPARATOR
Intervention: Reasons for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care.
Number of subjects: 1528
Study 8878716 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate (MPA) 5 mg b.i.d.
Number of subjects: 48
Study 8878716 — intervention group
Group type: EXPERIMENTAL
Intervention: dydrogesterone (DG) 10 mg b.i.d.
Number of subjects: 48
Study 1725022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril, 10 mg once daily for 4 weeks
Number of subjects: 100
Study 1725022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1725022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 100
Study 6838068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 39
Study 6838068 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 39
Study 31113725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin (100 mg/day for 3–10 days)
Number of subjects: 120
Study 31113725 — intervention group
Group type: COMPARATOR
Intervention: Garenoxacin (400 mg/day for 3–10 days)
Number of subjects: 120
Study 31113725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Number of subjects: 120
Study 31113725 — intervention group
Group type: COMPARATOR
Intervention: Garenoxacin
Number of subjects: 120
Study 29963797 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) angioplasty
Number of subjects: 187
Study 29963797 — intervention group
Group type: COMPARATOR
Intervention: Conventional bypass surgery
Number of subjects: 187
Study 26663712 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 169
Study 26663712 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 169
Study 26663712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 24844530 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) program in Manga format, delivered over six weeks with one lesson per week
Number of subjects: 381
Study 24844530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 381
Study 22322156 — intervention group
Group type: EXPERIMENTAL
Intervention: Qlaira (estradiol plus dienogest) for 9 to 11 days before surgery
Number of subjects: 74
Study 22322156 — intervention group
Group type: COMPARATOR
Intervention: Proliferative phase (cycle day 5‐7) without Qlaira
Number of subjects: 74
Study 20334707 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g of marine n-3 PUFA daily for 12 weeks
Number of subjects: 92
Study 20334707 — intervention group
Group type: COMPARATOR
Intervention: Control oil daily for 12 weeks
Number of subjects: 92
Study 18689157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care for hemophilia with inhibitors as per regional consensus and clinical guidelines.
Number of subjects: 3000
Study 15639064 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg / Ethinyl Estradiol 30 microg (DRSP/EE)
Number of subjects: 0
Study 15639064 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 150 microg / Ethinyl Estradiol 30 microg (LNG/EE)
Number of subjects: 0
Study 12717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumagillin
Number of subjects: 12
Study 12717629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10233563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desmopressin
Number of subjects: 17
Study 10233563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (25 IU/ml of mixture)
Number of subjects: 50
Study 8942381 — intervention group
Group type: COMPARATOR
Intervention: Control (standard mixture of local anaesthetic: 0.5% bupivacaine and 2% lignocaine in a 1:1 ratio without hyaluronidase)
Number of subjects: 50
Study 1714670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-9 100 pmol/kgh
Number of subjects: 18
Study 1714670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-9 500 pmol/kgh
Number of subjects: 18
Study 31336633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (150 mL, 10.5 mmol nitrate)
Number of subjects: 24
Study 31336633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mL, 1 mmol nitrate)
Number of subjects: 24
Study 30380279 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH laryngoscope
Number of subjects: 37
Study 30380279 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 37
Study 23171659 — intervention group
Group type: EXPERIMENTAL
Intervention: Online disease management intervention (n=193) including wirelessly uploaded glucometer readings, patient-specific reports, nutrition and exercise logs, insulin records, online messaging, nurse and dietitian support, and educational content.
Number of subjects: 415
Study 23171659 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=189)
Number of subjects: 415
Study 23171659 — intervention group
Group type: EXPERIMENTAL
Intervention: Online disease management intervention (n=193)
Number of subjects: 415
Study 22055636 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of data and feedback processes by frontline staff
Number of subjects: 126
Study 22055636 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of data and feedback processes by managers
Number of subjects: 126
Study 22055636 — intervention group
Group type: EXPERIMENTAL
Intervention: Information from mandated databases and feedback processes
Number of subjects: 126
Study 20214224 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules (14.22 g/day)
Number of subjects: 65
Study 20214224 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 17145182 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LET)
Number of subjects: 104
Study 17145182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 104
Study 14722412 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash subjects with mild, moderate, or severe pain and disability
Number of subjects: 80
Study 14722412 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe whiplash groups
Number of subjects: 80
Study 14722412 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash subgroups
Number of subjects: 80
Study 14722412 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 80
Study 11778799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11778799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction
Number of subjects: 61
Study 11778799 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scores (VAS)
Number of subjects: 61
Study 11778799 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic respiratory disease questionnaire (CRQ)
Number of subjects: 61
Study 9302131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 microg alprostadil alfadex (prostaglandin E1)
Number of subjects: 24
Study 9302131 — intervention group
Group type: COMPARATOR
Intervention: 30-minute intravenous infusion of 20 microg alprostadil alfadex (prostaglandin E1)
Number of subjects: 24
Study 8193494 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular, aluminium‐adsorbed diphtheria‐tetanus vaccine
Number of subjects: 235
Study 8193494 — intervention group
Group type: COMPARATOR
Intervention: Non‐adsorbed diphtheria‐tetanus vaccine
Number of subjects: 235
Study 3332574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg, 60 mg, or 90 mg once daily)
Number of subjects: 49
Study 3332574 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (80 mg, 160 mg, or 240 mg once daily)
Number of subjects: 49
Study 30640688 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (RALS)
Number of subjects: 96
Study 30640688 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 96
Study 28218596 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise
Number of subjects: 17
Study 28218596 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary aerobic exercise
Number of subjects: 17
Study 28218596 — intervention group
Group type: COMPARATOR
Intervention: Repetitive task practice only
Number of subjects: 17
Study 26449739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy (375 mg/m² every 3 months for 2 years)
Number of subjects: 321
Study 26449739 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 321
Study 23949063 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multidisciplinary rehabilitation
Number of subjects: 19
Study 21497851 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 300 U
Number of subjects: 57
Study 21497851 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study 19338146 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) pre-treated group
Number of subjects: 133